menu
    • menu
    [{"orgOrder":0,"company":"Beijing Union Pharmaceutical Factory","sponsor":"R&G PharmaStudies Co","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buagafuran","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Beijing Union Pharmaceutical Factory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Union Pharmaceutical Factory \/ R&G PharmaStudies Co","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Union Pharmaceutical Factory \/ R&G PharmaStudies Co"},{"orgOrder":0,"company":"Beijing Union Pharmaceutical Factory","sponsor":"R&G PharmaStudies Co","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buagafuran","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Beijing Union Pharmaceutical Factory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Union Pharmaceutical Factory \/ R&G PharmaStudies Co","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Union Pharmaceutical Factory \/ R&G PharmaStudies Co"},{"orgOrder":0,"company":"Beijing Union Pharmaceutical Factory","sponsor":"Beijing Union Pharmaceutical Factory","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bicyclol","moa":"Hepatocyte Cell","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Beijing Union Pharmaceutical Factory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Union Pharmaceutical Factory \/ Beijing Union Pharmaceutical Factory","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Union Pharmaceutical Factory \/ Beijing Union Pharmaceutical Factory"},{"orgOrder":0,"company":"Beijing Union Pharmaceutical Factory","sponsor":"Beijing Union Pharmaceutical Factory","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bicyclol","moa":"Hepatocyte Cell","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Beijing Union Pharmaceutical Factory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Union Pharmaceutical Factory \/ Beijing Union Pharmaceutical Factory","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Union Pharmaceutical Factory \/ Beijing Union Pharmaceutical Factory"}]

    Find Clinical Drug Pipeline Developments & Deals by Beijing Union Pharmaceutical Factory

    Menu

    Beijing Union Pharmaceutical Factory

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Beijing Union Pharmaceutical Factory

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beijing Union Pharmaceutical Factory

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buagafuran

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : R&G PharmaStudies Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase â…¢ Clinical Trial of Buagafuran Capsules in the Treatment of GAD

                            Details : Buagafuran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Generalized Anxiety Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 06, 2024

                            Lead Product(s) : Buagafuran

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : R&G PharmaStudies Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Beijing Union Pharmaceutical Factory

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beijing Union Pharmaceutical Factory

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buagafuran

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : R&G PharmaStudies Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

                            Details : Buagafuran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Generalized Anxiety Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 06, 2024

                            Lead Product(s) : Buagafuran

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : R&G PharmaStudies Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Beijing Union Pharmaceutical Factory

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beijing Union Pharmaceutical Factory

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bicyclol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Recipient : Drug Induced Liver Disease Study Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Multi-Center, Randomized, Double-blind, Positive Controlled Clinical Trial of Bicyclol in the Treatment of...

                            Details : Bicyclol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemical and Drug Induced Liver Injury.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 01, 2021

                            Lead Product(s) : Bicyclol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Recipient : Drug Induced Liver Disease Study Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Beijing Union Pharmaceutical Factory

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beijing Union Pharmaceutical Factory

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bicyclol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Recipient : Drug Induced Liver Disease Study Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DI...

                            Details : Bicyclol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemical and Drug Induced Liver Injury.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2016

                            Lead Product(s) : Bicyclol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Recipient : Drug Induced Liver Disease Study Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth